Human Papilloma Virus
Today, on International HPV Awareness Day, we take a moment to reflect on the impact of HPV and reaffirm our commitment to advancing research, awareness, and prevention. At KAVI-ICR and KEMRI, we are actively engaged in critical research aimed at understanding HPV persistence, clearance, and the immune responses that shape disease outcomes.
Through our ongoing work, supported by the Bill & Melinda Gates Foundation, we are exploring the role of HLA diversity in HPV infection and how this knowledge can guide the development of a therapeutic HPV vaccine. Our research, particularly in adolescent girls and young women, is designed to provide crucial insights that will inform prevention and treatment strategies, ultimately reducing the burden of HPV-related cancers.
As one of our PhD researchers Loise Nthambi from the Department of Medical Microbiology & Immunology at UoN aptly puts it:
"Our research reflects the motto prevention meets innovation! Mapping HLA-HPV interactions is more than research—it’s a step towards designing a therapeutic vaccine, thus a world where HPV infection-related cancers will be history."
On this day, we stand with global partners, healthcare professionals, researchers, and advocates to push for increased HPV vaccination, screening, and education. Together, we can move closer to a world where cervical cancer is preventable, and no one suffers needlessly from HPV-related diseases.
Let’s keep the conversation going. Awareness saves lives!
- Log in to post comments
